Talking to Manufacturing Chemist, Dr. Andrew Lewis, Chief Scientific Officer, shares his perspective on key trends, challenges, and opportunities shaping the years ahead for the pharma industry.
When asked about the most significant industry shifts or developments in 2025, Dr. Lewis emphasized a transformation driven by scientific innovation, digital integration and global dynamics. Biotech venture capital funding continued the trend of fewer but larger investments with several companies raising “megarounds” in excess of $100 million. This has caused a structural shift in the wider biotech ecosystem, which may be felt for some time.
Dr. Lewis also noted the rise of the Chinese biotech industry, with approximately 40% of the drugs in-licensed by pharmaceutical companies this year being discovered in China. Already a significant player in the CDMO space, it is now a significant force in biotech innovation.
When asked on trends and challenges anticipated for 2026, Dr. Lewis highlighted the growing use of AI across the pharma industry globally to streamline and improve the drug development process.
Read the full article on the Manufacturing Chemist site here.